Results 141 to 150 of about 1,359 (188)

Droxidopa or Atomoxetine for Refractory Hypotension in Critically Ill Cardiothoracic Surgery Patients.

Journal of Cardiothoracic and Vascular Anesthesia, 2023
OBJECTIVE To evaluate the effects of droxidopa or atomoxetine on intravenous (IV) vasoactive agent discontinuation in cardiothoracic intensive care unit (ICU) patients with hypotension refractory to midodrine. DESIGN Single-center, retrospective cohort
Julia Lessing, Shawn J. Kram, Jerrold H. Levy, L. Grecu, Jason N. Katz   +4 more
semanticscholar   +1 more source

The effect of ultrasonic irradiation on the morphology of NiO/Co3O4 nanocomposite and its application to the simultaneous electrochemical determination of droxidopa and carbidopa

Ultrasonics Sonochemistry, 2019
Mohammad Mehdi Foroughi, Shohreh Jahani, Maryam Kazemipour   +2 more
exaly   +2 more sources

Simultaneous determination of droxidopa and carbidopa by carbon paste electrode functionalized with NiFe2O4 nanoparticle and 2-(4-ferrocenyl-[1,2,3]triazol-1-yl)-1-(naphthalen-2-yl) ethanone

Measurement: Journal of the International Measurement Confederation, 2020
Sayed Zia Mohammadi, Hadi Beitollahi, Massoud Kaykhaii   +2 more
exaly   +2 more sources

Oral Vasoactive Medications: A Summary of Midodrine and Droxidopa as Applied to Orthostatic Dysfunction

Cardiology: Open Access, 2022
This is a summary of the uses and applications of two vasoactive drugs, Midodrine (ProAmatine) and Droxidopa (Northera), in the treatment of Orthostatic Dysfunction (OD) disorders, including Neurogenic Orthostatic Hypotension, Postural Orthostatic ...

semanticscholar   +1 more source

Droxidopa for neurogenic orthostatic hypotension [PDF]

Expert Opinion on Orphan Drugs, 2015
Introduction: Neurogenic orthostatic hypotension is a disabling manifestation of autonomic failure seen in disorders such as multiple system atrophy, pure autonomic failure, Lewy body disease, Parkinson’s disease, autonomic neuropathies and dopamine β-hydroxylase deficiency.Areas covered: Droxidopa is an orally administered norepinephrine prodrug that ...
openaire   +1 more source

Droxidopa for orthostatic hypotension

Journal of Hypertension, 2016
The systematic review and meta-analysis aims to determine the efficacy and safety of droxidopa in the treatment of orthostatic hypotension, following its recent approvals in the United States.MEDLINE, EMBASE, PubMed, Cochrane Controlled Trials Register, Web of Science, ProQuest, and the WHO Clinical Trials Registry were searched.
Julia L Newton, Maw Pin Tan, James Frith
exaly   +4 more sources

Droxidopa in the Treatment of Postural Orthostatic Tachycardia Syndrome

American Journal of Therapeutics, 2017
Background: Postural orthostatic tachycardia syndrome (POTS) is a constellation of signs and symptoms that occur when a patient is upright and relieved by recumbence. Currently, no drugs are labeled for the treatment for POTS.
Mohammed Ruzieh, Osama Dasa, Blair P Grubb   +2 more
exaly   +4 more sources

Pilot Study of Droxidopa With Carbidopa in Adults With ADHD

Journal of Attention Disorders, 2015
Objective: We conducted a two-period (open-label and double-blind) pilot investigation of droxidopa, with and without carbidopa, for ADHD. Method: Twenty adult ADHD patients received open-label droxidopa titrated from 200 to 600 mg 3 times per day (TID; Weeks 1-3), then open-label droxidopa plus carbidopa titrated from 25 or 50 mg TID (Weeks 4-6).
Stephen W. Gorny, Lenard A. Adler
openaire   +3 more sources

Use of Droxidopa to Treat Orthostatic Hypotension in a Patient With Hfref

Journal of Cardiac Failure, 2020
Background Orthostatic hypotension in patients with a low ejection fraction has been associated with a very high morbidity and mortality. Some of this is due to co-morbidity and some is due to the inability to use conventional medications such as ACE inhibitors, ARBs, sacubitril/valsartan and beta blockers because of worsening hypotension.
Sandra B. Charlton, Frank McGrew, Brian Dragutsky   +2 more
openaire   +2 more sources

Abstract 4145249: THE TWO-HIT HYPOTHESIS?: NEW ONEST SEVERE CARDIOMYOPATHY AND CARDIAC ARRYTHMIA IN A HIGH RISK PATIENT WITH NEUROGENIC ORTHOSTATIC HYPOTENSION ON DROXIDOPA

Circulation
Introduction: Droxidopa (DD) is the second FDA approved drug after midodrine for neurogenic orthostatic hypotension (nOH). Isaacon et al reported that 19 (5.4%) of total 350 patients on droxidopa had 25 cardiac events, most commonly atrial ...
Y. N. Htay, Varun Victor, Lakshmi Murugesan, Thi Ri, Dilanthy R. Annappah, Billal Sikandar, Ataul Qureshi, Ryan Koene   +7 more
semanticscholar   +1 more source